Celebrex Before Prostate Surgery Ineffective, Study

NSAID Made No Difference to Cancer Growth

To see whether Celebrex (celecoxib) can reduce prostate cancer size and spread, a team from several leading US cancer centers led by Dr. Alan Partin and Dr. Michael Carducci conducted a randomized, double-blind trial enrolling high-risk men before primary treatment with surgery or radiation. They measured the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy on these men.

Androgen Blockade For Metastatic Prostate Cancer

Dr. Gerald Chodak outlines controversy over antiandrogens

Men fighting metastatic prostate cancer may be frustrated to discover that doctors disagree with one another. For example, a lot of controversy surrounds the question of whether to block male hormones from the adrenal gland by use of a drug such as bicalutamide (Casodex). In a video, Dr. Gerald Chodak, a Chicago urologist, discusses how to maximize survival.

PSA Velocity May be Irrelevant in Detection of Prostate Cancer

Measuring velocity of prostate cancer specific antigen rise over time may not be necessary before deciding whether a man needs a prostate biopsy, according to a large new study from urologists at US and European cancer centers.

 PSA velocity (PSAV) is a term used for change PSA levels in the blood over time. Instead of basing a decision to recommend biopsy (or not) on a single annual PSA reading, the urologist looks at a series of tests and calculates the rate of rise over time.

The new study suggests that calculating PSA velocity does not help to detect prostate cancer once PSA and age are taken into consideration.

This finding was reported by European Association of Urolog this August. “Some guidelines,” Scardino notes, “do incorporate PSAV cut points as an indication for biopsy.”

Older Prostate Cancer Patients’ Chances Improved in 1990s

Since prostate cancer screening increased, more older men are surviving the disease through Active Surveillance, aka “Watchful Waiting”

Older men who were diagnosed with prostate cancer after early 1990 and were treated with conservative management (“Watchful Waiting”) lived significantly longer than men in similar situation 10 or 20 years previous to that.

This is the finding of a large new study based on Medicare patients’ records. The study is published in September 15 issue of the Journal of the American Medical Association (JAMA) by a team at The Cancer Institute of New Jersey (CINJ).

First Evidence of Virus Link to Some Prostate Cancers

A type of virus known to cause leukemia and sarcomas in animals has been found for the first time in human prostate cancer cells, according to researchers at the University of Utah and Columbia University medical schools. Their discovery may help in identifying a viral cause of prostate cancer.This would open opportunities for developing diagnostic tests, vaccines, and therapies for treating the cancer.

The researchers say they found the XMRV virus in almost a third of the prostate tumors they looked at.

“We found that XMRV was present in 27 percent of prostate cancers we examined and that it was associated with more aggressive tumors,” said Ila R. Singh, M.D., Ph.D., associate professor of pathology at University of Utah and the study’s senior author. “We still don’t know that this virus causes cancer in people, but that is an important question we’re going to investigate.”

New Look at Side Effects of Androgen Deprivation Therapy for Prostate Cancer

Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis.  A new review of the data suggests that the absolute increases in these risks are fairly low, but proper care is essential to minimize them.

AUA New Guidelines on Prostate Cancer Screening

The American Urological Association (AUA) today issued new clinical guidance about prostate cancer screening. The guidelines were announced at the association’s annual meeting by Peter Carroll, chair of the panel that developed the Statement.  The AUA states that its guidelines directly contrast with recent recommendations issued by other major groups.

AUA advises that the prostate-specific antigen (PSA) test should be offered to well-informed men aged 40 years or older who have a life expectancy of at least 10 years.